<DOC>
	<DOC>NCT00708084</DOC>
	<brief_summary>The aim of this study is to evaluate the safety of the monoclonal antibody cocktail CL184 in combination with rabies vaccine compared with human rabies immune globulin (HRIG) in combination with rabies vaccine in healthy children and adolescents.</brief_summary>
	<brief_title>Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Rabies</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins, Intravenous</mesh_term>
	<mesh_term>Rho(D) Immune Globulin</mesh_term>
	<criteria>Subjects free of obvious healthproblems or with stable conditions Male or female subject aged ≥5 to ≤18 years Subject is living, studying, or working close to the study referral site Parent or legal representative signed written informed consent; in addition for subjects ≥12 years: signed assent form Prior history of rabies exposure or immunization (rabies vaccine and/or immune globulin) Acute infection or disease within the last 2 weeks History and/or family history of clinically significant immunodeficiency or autoimmune disease Any history of known or suspected anaphylaxis or hypersensitivity reaction Planned immunization with live vaccines during the next 3 months Chronic administration of immunosuppressants or other immunemodifying drugs within 6 months before the first dose of investigational medicinal product</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Rabies post-exposure prophylaxis</keyword>
	<keyword>Monoclonal antibody</keyword>
</DOC>